With almost 200 inmates in the correctional facility in the community, 165 inmates are reported to have one of the three diseases. While in custody, the sheriff’s office and ultimately the tax payers are paying for the cost of medical treatment and medications to help these diseases. While out of a correctional facility in the community, a majority of all users do not have health insurance. With Hepatis C being the most common, it puts us in an ethical dilemma. A new drug has been made, called Harvoni, which is $94,500 for a twelve-week cycle, that can cure Hepatis C. The new drug is breaking the TennCare, while pulling the drug can save millions yearly, what about the effects it has on the victims of it has on the victims. Is cutting this funding worth it? What other ethical dilemma, that could save possibly even more
With almost 200 inmates in the correctional facility in the community, 165 inmates are reported to have one of the three diseases. While in custody, the sheriff’s office and ultimately the tax payers are paying for the cost of medical treatment and medications to help these diseases. While out of a correctional facility in the community, a majority of all users do not have health insurance. With Hepatis C being the most common, it puts us in an ethical dilemma. A new drug has been made, called Harvoni, which is $94,500 for a twelve-week cycle, that can cure Hepatis C. The new drug is breaking the TennCare, while pulling the drug can save millions yearly, what about the effects it has on the victims of it has on the victims. Is cutting this funding worth it? What other ethical dilemma, that could save possibly even more